Status:
RECRUITING
The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.
Lead Sponsor:
Novosibirsk Scientific Research Institute for Circulatory Pathology
Conditions:
to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting
Eligibility:
All Genders
18-90 years
Brief Summary
Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coron...
Detailed Description
Acetylsalicylic acid is indicated for the prevention of cardiovascular complications after CABG. Class I. The level of evidence A. ECS recommendations, Russian recommendations of cardiologists. Howeve...
Eligibility Criteria
Inclusion
- Stable ischemic disease 2- 4
- CABG
Exclusion
- the need to take any anticoagulants
- thrombocytopenia
- allergy to aspirin.
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06215300
Start Date
December 1 2022
End Date
November 1 2025
Last Update
January 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novosibirsk research institute of circulation pathology
Novosibirsk, Novosibirsk Oblast, Russia, 630055
2
Aleksey
Novosibirsk, Russia